Is combining abiraterone acetate with MDV3100 going to be clinically beneficial in mCRPC?

Posted on May 2, 2012 by Sitemaster

An article just published in Cancer Research this week suggests that adding the investigational agent enzalutamide (MDV3100) to abiraterone acetate and prednisone in men being treated for metastatic, castration-resistant prostate cancer (mCRPC) may be able to further delay disease progression among men showing signs of progression after initial treatment with abiraterone acetate.

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , | 2 Comments »

Can we use prostate cancer to develop national trial registry systems?

Posted on May 1, 2012 by Sitemaster

The April issue of AUA News (a magazine only available to AUA members) includes an interesting article by David Penson, MD, in which he previews a lecture he will be giving at the upcoming annual meeting of the American Urological Association (in Atlanta, later this month).

Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: , , , , , , | 6 Comments »

Nutrition and exercise guidance for cancer survivors

Posted on April 27, 2012 by Sitemaster

In an article just published in CA: A Cancer Journal for Clinicians, the American Cancer Society has updated its guidance to cancer survivors about things like diet, exercise, and the use of dietary supplements in managing quality of life and survival during and after treatment for cancer.

Filed under: Living with Prostate Cancer, Management | Tagged: , , , , | 3 Comments »

Can the PACE study resolve key questions about treatment of localized prostate cancer?

Posted on April 26, 2012 by Sitemaster

According to a media release from Accuray, Inc., the company has initiated a multi-center, multinational clinical trial in Europe to compare the outcomes of patients with localized prostate cancer treated with CyberKnife stereotactic body radiation therapy (SBRT), da Vinci robot-assisted laparoscopic surgery (RALP),  manual laparoscopic surgery (LRP), and conventionally fractionated intensity modulated radiation therapy (IMRT).

Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: , , , , , | 3 Comments »

Laboratory data suggests carvacrol may have anti-prostate cancer activity

Posted on April 25, 2012 by Sitemaster

A presentation at the Experimental Biology 2012 meeting in San Diego this week has suggested that carvacrol (a chemical found in the herb oregano) has activity against prostate cancer cells in laboratory tests. We hasten to point out that this sort of test does not necessarily mean that carvacrol would ever be shown to have [...]

Filed under: Drugs in development, Living with Prostate Cancer, Management | Tagged: , , , | 2 Comments »

Sexual function and serum T levels, before, on, and after 9 months of ADT

Posted on April 23, 2012 by Sitemaster

As many readers of this news service will be aware, good data on the recovery of libido and sexual function after a period of androgen deprivation therapy (ADT) are limited. We have long known that such recovery is variable, and we also know that it can take time, but sound data from a large cohort [...]

Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , , , , | 4 Comments »

Potential years of life lost due to prostate cancer in the USA: 1972-2006

Posted on April 20, 2012 by Sitemaster

An analysis published by Kamel et al. in the Journal of Urology earlier this year offers an estimate of the potential years of life lost (PYLL) due to prostate cancer in seven 5-year periods between 1972 and 2006. (Prostate cancer was the most prevalent of several forms of urogenital cancer addressed in this report.)

Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: , , , , | Leave a Comment »

The Berkshire Hathaway effect on prostate cancer management

Posted on April 18, 2012 by Sitemaster

As many readers will be aware, the Sage of Omaha, Warren Buffett, chairman and CEO of Berkshire Hathaway, announced yesterday that he has been diagnosed with prostate cancer that is “not remotely life threatening.” He does intend, however, to undergo 8 weeks of radiation therapy. Mr. Buffet is 81 years of age.

Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: , , , | 6 Comments »

What’s new in the Journal of the Canadian Urologic Association?

Posted on April 18, 2012 by Sitemaster

The April issue of the Journal of the Canadian Urologic Association offers the interested reader access to the full texts of a small number of topical articles. None of them could be considered “game changing” in terms of current prostate cancer management today … but certainly thought-stimulating.

Filed under: Diagnosis, Living with Prostate Cancer, Management, Prevention, Risk | Tagged: , , , , , , | Leave a Comment »

Can the new hormone therapies actually replace the older ones?

Posted on April 17, 2012 by Sitemaster

Here is a question that is on the minds of many physicians and patients on Planet Prostate Cancer today: Can treatment with abiraterone acetate or similar agents replace the continuous and/or the intermittent first-line use of LHRH-agonist–induced medical castration in patients with high-risk and advanced forms of prostate cancer?

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , | 8 Comments »

Relative value of 3D-CRT, IMRT, and PBRT in prostate cancer published in JAMA

Posted on April 17, 2012 by Sitemaster

In February we reported on a presentation by Sheets et al. at the Genitourinary Cancer Symposium. The presentation addressed the comparative effectiveness and safety of  3D conformal, intensity-modulated, and proton beam forms of radiation therapy (3D-CRT, IMRT, and PBRT, respectively).

Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , , , | Leave a Comment »

Focal HIFU in men with localized prostate cancer — data from a small, initial, UK trial

Posted on April 17, 2012 by Sitemaster

A report just published on line in The Lancet Oncology provides data from a study of the use of focally directed (as opposed to whole gland) high-intensity focused ultrasound (HIFU) in the treatment of a small series of men with localized prostate cancer between 2007 and 2010. The data are interesting but follow-up to date [...]

Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , , | 12 Comments »

mCRPC patients in UK can participate in Phase III trial of Prostvac VF

Posted on April 16, 2012 by Sitemaster

According to a story in the UK’s Daily Telegraph this morning, the British government has given approval for eligible patients in the UK to participate in the randomized, Phase III trial of Prostvac VF — a new form of immunotherapy being tested in men with metastatic, castration-resistant prostate cancer (mCRPC).

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , | Leave a Comment »

The radium-223 expanded access clinical trial

Posted on April 16, 2012 by Sitemaster

Just a quick update to information about expanded access to treatment with radium-223 — the injectable form of radiation therapy currently being developed by Bayer Healthcare and Algeta.

Filed under: Drugs in development, Living with Prostate Cancer, Management | Tagged: , , , , | Leave a Comment »

Have we lost all economic sense of reality about cancer treatment in America?

Posted on April 12, 2012 by Sitemaster

There may be a very small number of regular readers of this column that would consider it perfectly OK to spend $200,000 to have exclusive personal use of a high performance car like a Maserati GranTurismo MC Stradale for a single year. Good luck to them; they clearly have the annual income to afford it. [...]

Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: , , | 8 Comments »

« Previous Page — Next Page »
Follow

Get every new post delivered to your Inbox.

Join 325 other followers